Phenethyl Lactam PDE4 Inhibitor for Lung-Targeted COPD Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for chronic obstructive pulmonary disease (COPD) do not effectively slow the progression of the disease or reduce mortality, and existing phosphodiesterase-4 (PDE4) inhibitors like roflumilast have dose-dependent side effects that limit their clinical use.
Innovation Solution
Development of a 3,4-alkoxy substituted phenethyl lactam compound as a phosphodiesterase inhibitor, specifically targeting PDE4, which is designed to inhibit PDE activity and elevate intracellular cAMP levels for anti-inflammatory effects, with a focus on pulmonary administration to enhance lung retention and reduce side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If PDE4 inhibitors like roflumilast are used to treat COPD, then anti-inflammatory effect is improved, but dose-dependent side effects (nausea, vomiting) worsen
Solution Approach 1:
The patent modifies the PDE4 inhibitor structure by introducing a 3,4-alkoxy substituted phenethyl lactam moiety with specific substituents (R1-R4) to create local chemical differences that enhance lung tissue affinity and selectivity. This local structural modification allows the drug to exert stronger anti-inflammatory effects in the lung while reducing systemic side effects through increased tissue-specific targeting.
Solution Approach 2:
The patent systematically varies chemical parameters (substituents R1-R4, their positions, and molecular weight) to optimize the balance between anti-inflammatory activity and side effect profile. By changing these molecular parameters, the compound achieves potent PDE4 inhibition in the lung while minimizing gastrointestinal and central nervous system effects.
2Ease of operation
If existing COPD drugs are used, then symptom management is improved, but long-term disease progression is not slowed
Solution Approach 1:
The patent designs a PDE4 inhibitor with optimized pharmacokinetic properties (half-life, clearance) to ensure continuous anti-inflammatory action in the lung. The compound's structural features (hydrophilic substituents, molecular weight) promote sustained presence in lung tissue, providing continuous inhibition of PDE4 and thus continuous suppression of inflammatory pathways, which may slow disease progression over time.
3Reliability
If PDE4 inhibitors are administered systemically, then anti-inflammatory effect is achieved, but compliance is reduced due to severe side effects
Solution Approach 1:
The patent creates a PDE4 inhibitor with enhanced lung tissue affinity through specific structural features (3,4-alkoxy substituted phenethyl lactam core with hydrophilic substituents). This local targeting allows the drug to achieve effective anti-inflammatory concentrations in the lung at lower systemic doses, reducing side effects and improving patient compliance.
Solution Approach 2:
The patent introduces a prodrug strategy where the compound can be administered in a form that is activated in the lung tissue. The structural design allows for potential first-pass metabolism or activation mechanisms that convert the administered form into the active PDE4 inhibitor specifically in the lung, reducing systemic exposure and side effects while maintaining therapeutic effect.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compound exhibits potent inhibitory activity against PDE4B1 enzyme and TNF-α release, showing a relatively short half-life and strong affinity for lung tissue, providing a promising anti-inflammatory effect with reduced side effects.
Implementation Method 1
PDEs promote the degradation of cAMP into 5'-AMP, an inactive product. Therefore, intracellular cAMP levels can be elevated to achieve the broad-spectrum anti-inflammatory purpose by the targeted inhibition of the activity of PDEs
Implementation Method 2
The elevation of the intracellular cAMP level can regulate a variety of inflammatory mediators, thereby achieving a broad-spectrum anti-inflammatory effect. The balance of CAMP in vivo is mainly regulated by adenyl cyclase (CA) and phosphodiesterases (PDEs), in which CA catalyzes the synthesis of cAMP from ATP
Data Source
AI summary
The present disclosure pertains to the technical field of pharmaceutics, and relates to a 3,4-alkoxy substituted phenethyl lactam compound as an enzyme inhibitor of phosphodiesterases, a preparation method therefor, and pharmaceutical use thereof. Specifically, the present disclosure relates to a compound represented by general formula (I), a preparation method therefor, and use thereof in a medicament for preventing and/or treating a phosphodiesterase-associated disease.